VYVGART is the first neonatal Fc receptor (FcRn) blocker approved in Europe for the treatment of adults living with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive
68% of anti-AChRantibody positive gMG patients treated with VYVGART were responders (n=44/65) on the Myasthenia GravisActivities of Daily Living (MG-ADL) scale compared with 30% of patients treated with placebo (n=19/64) (p